Welcome to our dedicated page for Ainos news (Ticker: AIMD), a resource for investors and traders seeking the latest updates and insights on Ainos stock.
Ainos, Inc. (NASDAQ: AIMD) is a dual-platform AI and biotech company whose news flow is centered on its AI Nose SmellTech platform and related AI infrastructure, alongside development of its low-dose oral interferon candidate, VELDONA. Company updates frequently highlight progress in digitizing scent into Smell ID, expanding industrial deployments, and advancing its Smell Language Model (SLM) through its subsidiary ScentAI Inc.
On this page, readers can follow AIMD news related to industrial partnerships, commercialization milestones, and strategic agreements. Recent announcements have covered distribution and deployment partnerships in semiconductor front-end manufacturing, collaborations with industrial computing and edge AI providers, and expansion of AI Nose pilots across smart factories, robotics, and healthcare environments. Ainos also issues press releases on its GICS reclassification into the technology sector, intellectual property additions, and SmellTech-as-a-Service contracts.
Investors and observers can expect news items on topics such as multi-year SmellTech-as-a-Service agreements, pilot deployments in senior care and robotics, new patents for AI Nose and digital olfaction, and updates on the company’s platform strategy to separate sensing hardware (Ainos) from AI intelligence (ScentAI). Financial result releases and associated commentary provide additional context on research and development priorities and commercialization roadmaps.
By monitoring this news feed, users gain a consolidated view of how Ainos is building its SmellTech ecosystem across semiconductors, industrial automation, robotics, and healthcare, while continuing to develop its VELDONA oral interferon program. Bookmark this page for ongoing coverage of AIMD press releases, partnership announcements, and regulatory communications.
Ainos, Inc. (NASDAQ:AIMD, AIMDW) announced positive results from its preclinical efficacy study of VELDONA®, a low-dose oral interferon formulation, against the Omicron variant of SARS-CoV-2. The study demonstrated significant stabilization in lung inflammation and recovery in hamsters treated with VELDONA®. The results led to an application for Phase 2 clinical trials in patients with mild COVID-19. The treatment showed a better recovery trend, with no observed mixed-cellular inflammation in the VELDONA® group, compared to 50% in the placebo group.
Ainos, Inc. (NASDAQ:AIMD, AIMDW) has submitted an Investigational New Drug (IND) application to the U.S. FDA for a Phase 2 trial of its low-dose oral interferon (IFN)-alpha formulation, VELDONA, aimed at treating mild COVID-19 symptoms. The trial will assess VELDONA's efficacy compared to standard care in a multicenter study in Taiwan. If successful, this could enhance treatments for COVID-19 and other viral infections.
Ainos, Inc. (NASDAQ:AIMD, AIMDW) has announced a Master Service Agreement with Swiss Pharmaceutical Co., Ltd. to test, manufacture, and package its VELDONA product candidates. This agreement aligns with Ainos' plans to submit an IND application for a Phase 2 study to the FDA by year-end. Additionally, Ainos is pursuing clinical trials for VELDONA against COVID-19 and has plans for further studies on thrombocytopenia and Sjögren's syndrome in 2023. This partnership aims to enhance Ainos' manufacturing capabilities and streamline its clinical trial preparations.
Ainos, a diversified medtech company, reported its second quarter financial results for 2022, showing a substantial revenue increase of 213.6% to US$636,627, driven by sales of COVID-19 Antigen Rapid Test Kits. Gross profit reached US$317,664, with a gross margin of 49.9%. However, total operating expenses surged 163.0% to US$2,261,960, impacting net loss, which increased to US$1,954,032. The company highlighted successful product developments, including an Emergency Use Authorization for its COVID-19 test kit in Taiwan, and progress on its VELDONA antiviral formulation.
Ainos, Inc. (NASDAQ:AIMD, AIMDW) has announced the closing of its public offering of 780,000 units at $4.25 per unit, yielding approximately $3.3 million in gross proceeds. Each unit includes one share of common stock and a warrant for one share. The stock underwent a reverse split at a 1-for-15 ratio, effective August 8, 2022. Additionally, the company granted underwriters a 45-day option to purchase an extra 117,000 shares and/or warrants. The offering was conducted under its SEC registration statement, effective as of August 8, 2022.
Ainos, Inc. (OTC PINK: AIMD) announced positive results from a preclinical study of its oral interferon formulation, VELDONA, against COVID-19 in hamsters. The study showed that VELDONA significantly reduced weight loss and viral loads in infected hamsters compared to a control group. Notably, the VELDONA group exhibited a maximum viral load reduction of 720510.66 on day six. Ainos plans to prepare application documents for FDA Phase 2/3 clinical trials, aiming to establish VELDONA's efficacy against COVID-19 and other viral infections.
Ainos, Inc. (OTC PINK:AIMD) has launched the Ainos SARS-CoV-2 Antigen Rapid Self-Test Kit in Taiwan, following Emergency Use Authorization from the Taiwan Food and Drug Administration on June 13, 2022. This at-home test kit enables users to detect the presence of SARS-CoV-2, including the Omicron variant, yielding results in just 15 minutes. The company has previously marketed a professional-use version since June 2021. Ainos aims to meet the rising demand for COVID-19 testing amidst increasing cases, thereby supporting public health measures.
Ainos, Inc. (OTC PINK:AIMD) announced a partnership with InnoPharmax, Inc. to develop a combined therapy for COVID-19. The therapy will utilize Ainos' VELDONA® low-dose interferon platform and InnoPharmax's antiviral drug, GemOral®. The companies will conduct clinical trials in Taiwan and aim for Phase III trials by Q3 2022, targeting emergency use authorization in the U.S. The estimated cost per treatment is approximately USD 500, pending market conditions. This strategic collaboration aims to enhance antiviral treatment options as COVID-19 cases continue to rise.
Ainos, Inc. (OTC PINK:AIMD) announced significant early milestones in its mRNA vaccine development targeting the Delta variant of SARS-CoV-2. The company's synthetic RNA (SRNA) research is a key focus of its Preventive Medicine division. Ainos has designed a novel plasmid for universal viral gene expression suitable for extensive mRNA production. Preliminary formulations of liposome particles for mRNA delivery have been developed for efficacy testing in cell lines and animal models. Overall, Ainos aims to stimulate protective immunity against SARS-CoV-2 variants, enhancing public health response.
Ainos, Inc. (OTC PINK:AIMD) appointed Ms. Hui-Lan (Celia) Wu as its new Chief Financial Officer on August 16, 2021, succeeding Mr. Chun-Hsien Tsai, who remains the Chairman and CEO. Wu, with nearly 30 years of experience in accounting and management consulting, previously served as a partner at KPMG Taiwan. The company continues to invest in key personnel, including Lawrence Lin as Executive Vice President of Operations and John Junyong Lee as Chief Legal Counsel. Ainos focuses on rapid disease testing products, particularly for COVID-19.